Shares of Innoviva, Inc. (NASDAQ:INVA - Get Free Report) reached a new 52-week high during mid-day trading on Friday . The company traded as high as $19.87 and last traded at $19.83, with a volume of 28830 shares traded. The stock had previously closed at $19.61.
Wall Street Analyst Weigh In
Several research analysts have recently issued reports on INVA shares. Cantor Fitzgerald reiterated an "overweight" rating on shares of Innoviva in a report on Tuesday, July 30th. StockNews.com cut Innoviva from a "strong-buy" rating to a "buy" rating in a report on Tuesday, August 6th.
Check Out Our Latest Research Report on INVA
Innoviva Stock Performance
The stock has a 50 day moving average of $18.34 and a 200 day moving average of $16.44. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of 8.91 and a beta of 0.57. The company has a quick ratio of 11.40, a current ratio of 12.70 and a debt-to-equity ratio of 0.67.
Innoviva (NASDAQ:INVA - Get Free Report) last posted its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $0.68 EPS for the quarter. Innoviva had a net margin of 44.00% and a return on equity of 33.26%. The company had revenue of $99.90 million for the quarter. As a group, analysts predict that Innoviva, Inc. will post 0.5 EPS for the current year.
Institutional Trading of Innoviva
A number of large investors have recently bought and sold shares of the business. SageView Advisory Group LLC acquired a new stake in Innoviva during the first quarter worth approximately $1,555,000. Baader Bank Aktiengesellschaft bought a new stake in shares of Innoviva in the 4th quarter valued at $257,000. Hillsdale Investment Management Inc. acquired a new position in shares of Innoviva during the 4th quarter valued at $4,663,000. CWA Asset Management Group LLC acquired a new position in shares of Innoviva during the 4th quarter valued at $4,070,000. Finally, Boston Partners boosted its stake in Innoviva by 90.3% during the first quarter. Boston Partners now owns 391,456 shares of the biotechnology company's stock worth $5,966,000 after acquiring an additional 185,784 shares in the last quarter. 99.12% of the stock is currently owned by institutional investors and hedge funds.
About Innoviva
(
Get Free Report)
Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
Further Reading
Before you consider Innoviva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Innoviva wasn't on the list.
While Innoviva currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
